Avenanthramides, polyphenols from oats, exhibit anti-inflammatory and anti-itch activity

  • Runa Sur
  • Anu Nigam
  • Devon Grote
  • Frank Liebel
  • Michael D. Southall
Original Paper

Abstract

Oatmeal has been used for centuries as a soothing agent to relieve itch and irritation associated with various xerotic dermatoses; however few studies have sought to identify the active phytochemical(s) in oat that mediate this anti-inflammatory activity. Avenanthramides are phenolic compounds present in oats at approximately 300 parts per million (ppm) and have been reported to exhibit anti-oxidant activity in various cell-types. In the current study we investigated whether these compounds exert anti-inflammatory activity in the skin. We found that avenanthramides at concentrations as low as 1 parts per billion inhibited the degradation of inhibitor of nuclear factor kappa B-α (IκB-α) in keratinocytes which correlated with decreased phosphorylation of p65 subunit of nuclear factor kappa B (NF-κB). Furthermore, cells treated with avenanthramides showed a significant inhibition of tumor necrosis factor-α (TNF-α) induced NF-κB luciferase activity and subsequent reduction of interleukin-8 (IL-8) release. Additionally, topical application of 1–3 ppm avenanthramides mitigated inflammation in murine models of contact hypersensitivity and neurogenic inflammation and reduced pruritogen-induced scratching in a murine itch model. Taken together these results demonstrate that avenanthramides are potent anti-inflammatory agents that appear to mediate the anti-irritant effects of oats.

Keywords

Inflammation Itch Avenanthramide Cytokine NF-κB Keratinocyte 

Abbreviations

RTX

Resiniferatoxin

TNFα

Tumor necrosis factor-α

IL-8

Interleukin-8

NF-κB

Nuclear factor kappa beta

References

  1. 1.
    Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y (1995) Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 92:10599–10603PubMedCrossRefGoogle Scholar
  2. 2.
    Aries MF, Vaissiere C, Pinelli E, Pipy B, Charveron M (2005) Avena Rhealba inhibits A23187-stimulated arachidonic acid mobilization, eicosanoid release, and cPLA2 expression in human keratinocytes: potential in cutaneous inflammatory disorders. Biol Pharm Bull 28:601–606PubMedCrossRefGoogle Scholar
  3. 3.
    Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr (1993) Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol 13:3301–3310PubMedGoogle Scholar
  4. 4.
    Bernhard JD (1994) Scratching. Itch mechanisms and management of pruritus. McGraw-Hill, New YorkGoogle Scholar
  5. 5.
    Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U (1995) Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267:1485–1488PubMedCrossRefGoogle Scholar
  6. 6.
    Bryngelsson S, Dimberg LH, Kamal-Eldin A (2002) Effects of commercial processing on levels of antioxidants in oats (Avena sativa L.). J Agric Food Chem 50:1890–1896PubMedCrossRefGoogle Scholar
  7. 7.
    Chen CY, Milbury PE, Kwak HK, Collins FW, Samuel P, Blumberg JB (2004) Avenanthramides and phenolic acids from oats are bioavailable and act synergistically with vitamin C to enhance hamster and human LDL resistance to oxidation. J Nutr 134:1459–1466PubMedGoogle Scholar
  8. 8.
    Collins FW (1989) Oat phenolics: avenanthramides, novel substituted N-cinnamoylanthranilate alkaloids from oat groats and hulls. J Agric Food Chem 37:60–66CrossRefGoogle Scholar
  9. 9.
    Dick LA (1958) Colliodal emollient baths in pediatric dermatoses. Arch Pediatr 75:506–508PubMedGoogle Scholar
  10. 10.
    Dick LA (1962) Bath oils in dry, itchy dermatoses in children. Skin 1:341–342PubMedGoogle Scholar
  11. 11.
    Dimberg LH, Theander O, Lingert H (1993) Avenanthramides- a group of phenolic antioxidants in oats. Cereal Chem 70:637–641Google Scholar
  12. 12.
    Franks AG (1958) Dermatologic uses of baths. Am Pract Dig Treat 9:1998–2000PubMedGoogle Scholar
  13. 13.
    Guo W, Wise ML, Collins FW, Meydani M (2008) Avenanthramides, polyphenols from oats, inhibit IL-1beta-induced NF-kappaB activation in endothelial cells. Free Radic Biol Med 44:415–429PubMedCrossRefGoogle Scholar
  14. 14.
    Ishihara A, Miyagawa H, Matsukawa T, Ueno T, Mayama S, Iwamura H (1998) Induction of hydroxyanthranilate hydroxycinnamoyl transferase activity by oligo-N-acetylchitooligosaccharides in oats. Phytochemistry 47:969–974CrossRefGoogle Scholar
  15. 15.
    Ishihara A, Ohtsu Y, Iwamura H (1999) Biosynthesis of oat avenanthramide phytoalexins. Phytochemistry 50:237–242CrossRefGoogle Scholar
  16. 16.
    Koibuchi Y, Ichikawa A, Nakagawa M, Tomita K (1985) Histamine release induced from mast cells by active components of compound 48/80. Eur J Pharmacol 115:163–170PubMedCrossRefGoogle Scholar
  17. 17.
    Kurtz ES, Wallo W (2007) Colloidal oatmeal: history, chemistry and clinical properties. J Drugs Dermatol 6:167–170PubMedGoogle Scholar
  18. 18.
    Liebel F, Lyte P, Garay M, Babad J, Southall MD (2006) Anti-inflammatory and anti-itch activity of sertaconazole nitrate. Arch Dermatol Res 298:191–199PubMedCrossRefGoogle Scholar
  19. 19.
    Lippert U, Hoer A, Moller A, Ramboer I, Cremer B, Henz BM (1998) Role of antigen-induced cytokine release in atopic pruritus. Int Arch Allergy Immunol 116:36–39PubMedCrossRefGoogle Scholar
  20. 20.
    Liu L, Zubik L, Collins FW, Marko M, Meydani M (2004) The antiatherogenic potential of oat phenolic compounds. Atherosclerosis 175:39–49PubMedCrossRefGoogle Scholar
  21. 21.
    Maniatis T (1999) A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev 13:505–510PubMedCrossRefGoogle Scholar
  22. 22.
    Matsukawa T, Isobe T, Ishihara A, Iwamura H (2000) Occurrence of avenanthramides and hydroxycinnamoyl-CoA:hydroxyanthranilate N-hydroxycinnamoyltransferase activity in oat seeds. Z Naturforsch 55:30–36Google Scholar
  23. 23.
    Mayama S, Tani T, Matsuura Y (1981) The production of phytoalexins by oat in response to crown rust, Puccinia coronata f. sp. avenae. Physiol Plant Pathol 19:217–226Google Scholar
  24. 24.
    Mayama S, Matsuura Y, Iida H, Tani T (1982) The role of avenlumin in the resistance of oat to crown rust, Puccinia coronata f. sp. avenae. Physiol Plant Pathol 20:189–199CrossRefGoogle Scholar
  25. 25.
    O’Brasky L (1959) Management of extensive dry skin conditions. Conn Med 23:20–21PubMedGoogle Scholar
  26. 26.
    Richardson JD, Vasko MR (2002) Cellular mechanisms of neurogenic inflammation. J Pharm Exp Ther 302:839–845CrossRefGoogle Scholar
  27. 27.
    Rukwied R, Lischetzki G, McGlone F, Heyer G, Schmelz M (2000) Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br J Dermatol 142:1114–1120PubMedCrossRefGoogle Scholar
  28. 28.
    Saeed SA, Butt NM, McDonald-Gibson WJ, Collier HOJ (1981) Inhibitors of prostaglandin biosynthesis in extracts of oat (Aveena sativa) seeds. Biochem Soc Trans 9:444Google Scholar
  29. 29.
    Schmelz M, Handwerker HO (2003) Neurophysiologic basis of itch. In: Yosipovitch G, Greaves MW, Fleishcer AB, McGlone F (eds) Itch basic mechanisms and therapy. Marcel Dekker, New York, pp 5–20Google Scholar
  30. 30.
    Smith GC (1958) The treatment of various dermatoses associated with dry skin. J South Carol Med Assoc 54:282–283Google Scholar
  31. 31.
    Szallasi A, Blumberg PM (1989) Neurogenic component of phorbol ester-induced mouse skin inflammation. Cancer Res 49:6052–6057PubMedGoogle Scholar
  32. 32.
    Vie K, Cours-Darne S, Vienne MP, Boyer F, Fabre B, Dupuy P (2002) Modulating effects of oatmeal extracts in the sodium lauryl sulfate skin irritancy model. Skin Pharmacol Appl Skin Physiol 15:120–124PubMedCrossRefGoogle Scholar
  33. 33.
    Young JM, De Young LM (1989) Cutaneous models of inflammation for the evaluation of topical and systemic pharmacological agents. In: Chang JY, Lewis JA (eds) Pharmacol methods control inflammation. Alan R Liss Inc., New York, pp 215–231Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Runa Sur
    • 1
  • Anu Nigam
    • 1
  • Devon Grote
    • 1
  • Frank Liebel
    • 1
  • Michael D. Southall
    • 1
  1. 1.Preclinical PharmacologySkin Research Center, Johnson & Johnson Consumer ProductsSkillmanUSA

Personalised recommendations